Abstract
Leishmaniasis is a global disease, which has become a major health challenge for Pakistan and other developing countries. Infections caused by the parasitic protozoa constitute a major hindrance in socioeconomic development in many developing countries. In this study, we developed a topical application (gel), containing active ingredients derived from garlic, on which in vitro, in vivo, and clinical studies were conducted. Anti-leishmanial activity observed in vitro was followed by in vivo study with the application of this active ingredient, prepared in gel form, and applied once daily on experimental mouse model. Their lesions cured completely within 4-6 weeks. This was followed by clinical trials in humans. A total of 70 patients, 58 (82.85%) males, and 12 (17.14%) females, were selected with positive Leishmania parasites by smear examination. Out of 70 patients, 57 patients (81.42%) responded to the treatment, while 13 patients (18.57%) did not. Ten patients (17.54%) showed complete clinical recovery after 06 weeks of therapy, while 40 (70.17%) showed complete clinical recovery after 08 weeks of therapy. The results of this clinical study establish the efficacy, and cost effectiveness of garlic-based topical gel, and pave the way for further research in its therapeutic applications.
Keywords: Leishmaniasis, cutaneous leishmaniasis, clinical trials, garlic extract, topical applications, anti-leishmanial activity, In vitro studies
Anti-Infective Agents
Title:Laboratory Studies and Clinical Trials on New Formulations from Garlic Extract Against Cutaneous Leishmaniasis
Volume: 10 Issue: 2
Author(s): Azam J. Samdani, Samreen, M. Iqbal Choudhary and Atta-ur-Rahman
Affiliation:
Keywords: Leishmaniasis, cutaneous leishmaniasis, clinical trials, garlic extract, topical applications, anti-leishmanial activity, In vitro studies
Abstract: Leishmaniasis is a global disease, which has become a major health challenge for Pakistan and other developing countries. Infections caused by the parasitic protozoa constitute a major hindrance in socioeconomic development in many developing countries. In this study, we developed a topical application (gel), containing active ingredients derived from garlic, on which in vitro, in vivo, and clinical studies were conducted. Anti-leishmanial activity observed in vitro was followed by in vivo study with the application of this active ingredient, prepared in gel form, and applied once daily on experimental mouse model. Their lesions cured completely within 4-6 weeks. This was followed by clinical trials in humans. A total of 70 patients, 58 (82.85%) males, and 12 (17.14%) females, were selected with positive Leishmania parasites by smear examination. Out of 70 patients, 57 patients (81.42%) responded to the treatment, while 13 patients (18.57%) did not. Ten patients (17.54%) showed complete clinical recovery after 06 weeks of therapy, while 40 (70.17%) showed complete clinical recovery after 08 weeks of therapy. The results of this clinical study establish the efficacy, and cost effectiveness of garlic-based topical gel, and pave the way for further research in its therapeutic applications.
Export Options
About this article
Cite this article as:
J. Samdani Azam, Samreen , Iqbal Choudhary M. and Atta-ur-Rahman , Laboratory Studies and Clinical Trials on New Formulations from Garlic Extract Against Cutaneous Leishmaniasis, Anti-Infective Agents 2012; 10 (2) . https://dx.doi.org/10.2174/2211362611208020111
DOI https://dx.doi.org/10.2174/2211362611208020111 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer’s Disease
Current Drug Targets Lectin Microarrays: A Powerful Tool for Glycan-Based Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Fruitless Wolfberry-Sprout Extract Rescued Cognitive Deficits and Attenuated Neuropathology in Alzheimer’s Disease Transgenic Mice
Current Alzheimer Research Pulmonary Circulation and Pulmonary Function in Neonatal Lung Hypoplasia:Treatment with Corticosteroids
Current Pediatric Reviews Chitosan Formulations as Carriers for Therapeutic Proteins
Current Drug Discovery Technologies BMI1 Regulation of Self-Renewal and Multipotency in Human Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Molecular Genetics of Polycystic Ovary Syndrome: An Update
Current Molecular Medicine Meet Our Editorial Board Member:
Current Rheumatology Reviews Sexual Dimorphism in Autoimmune Disease
Current Molecular Medicine Innate Immunity and the Role of Epithelial Barrier During Aspergillus fumigatus Infection
Current Immunology Reviews (Discontinued) Can Increased Food Intake Improve Psychosis? A Brief Review and Hypothesis
Current Molecular Pharmacology Stimulator of Interferon Genes Signaling Pathway and its Role in Anti-tumor Immune Therapy
Current Pharmaceutical Design Isolation, Characterization, and Docking Studies of (Z)-Isopropyl 7-((1R, 2R, 3R, 5S)- 2-((1E, 3Z)-3-Fluoro-4-Phenoxybuta-1, 3-Dienyl)-3,5-Dihydroxycyclopentyl) Hept-5- Enoate, an Impurity of Tafluprost
Current Organic Synthesis Immunomodulatory Lactoferrin in the Regulation of Apoptosis Modulatory Proteins in Cancer
Protein & Peptide Letters Unique Coronary Artery Disease Differences in Women as Related to Revascularization
Current Medicinal Chemistry Microglia in Alzheimer’s Disease
Current Alzheimer Research Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Vasopressin and Oxytocin in Control of the Cardiovascular System
Current Neuropharmacology Simvastatin is Protective During Staphylococcus aureus Pneumonia
Current Pharmaceutical Biotechnology Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety